🔎 Trials Near Me

Home › Medulloblastoma

Medulloblastoma clinical trials recruiting in the U.S.

24 studies for Medulloblastoma are recruiting participants at sites across the United States.

Cities with the most studies

By state

Recently updated studies

Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease

RecruitingPhase 1/2
Ages 1 to 25 · All sexes · Updated Sep 28, 2026 · NCT07346157

Cognitive Rehabilitation for Survivors of Childhood Medulloblastoma Using Real Time Hemodynamic Neurofeedback

Recruiting
Ages 10 to 25 · All sexes · Updated Sep 23, 2026 · NCT07830134

Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

RecruitingPhase 2
59 Months · All sexes · Updated Sep 15, 2026 · NCT05535166

GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults

RecruitingPhase 1
Ages 1 to 30 · All sexes · Updated Sep 11, 2026 · NCT07087002

Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors

RecruitingPhase 2
Up to age 19 · All sexes · Updated Sep 10, 2026 · NCT01356290

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

RecruitingPhase 1
36 Months – 22 Years · All sexes · Updated Sep 4, 2026 · NCT03911388

B7-H3.CD28Z.CART in CNS Neoplasms

RecruitingPhase 1
Ages 2 to 21 · All sexes · Updated Sep 3, 2026 · NCT07390539

Relapsed and Progressive Sonic Hedgehog Medulloblastoma With U1 Mutation Registry Study

RecruitingObservational study
Ages 3 to 50 · All sexes · Updated Sep 1, 2026 · NCT07242963

Digoxin Medulloblastoma Study

RecruitingPhase 2
12 Months – 30 Years · All sexes · Updated Aug 26, 2026 · NCT06701812

A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss

RecruitingPhase 3
Ages 4 to 21 · All sexes · Updated Aug 25, 2026 · NCT05382338

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

RecruitingPhase 2
Ages 3 to 39 · All sexes · Updated Aug 24, 2026 · NCT05096481

DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma

RecruitingPhase 2
Up to age 21 · All sexes · Updated Aug 12, 2026 · NCT04696029

PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications

RecruitingPhase 1/2
Ages 18 to 120 · All sexes · Updated Aug 12, 2026 · NCT06161519

Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma

Recruiting
12 Months – 39 Years · All sexes · Updated Aug 11, 2026 · NCT05057702

Atovaquone Combined With Radiation in Children With Malignant Brain Tumors

RecruitingPhase 1
Ages 2 to 25 · All sexes · Updated Aug 3, 2026 · NCT06624371

Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors

RecruitingPhase 1/2
Ages 4 to 39 · All sexes · Updated Jul 20, 2026 · NCT05278208

CSIMEMPHIS: Long-term Follow-up of Medulloblastoma Survivors That Received Craniospinal Irradiation

RecruitingObservational study
All ages · All sexes · Updated Jul 6, 2026 · NCT07085325

Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)

RecruitingPhase 1
Ages 1 to 30 · All sexes · Updated Jun 17, 2026 · NCT06193759

Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer

RecruitingPhase 1
Ages 3 to 25 · All sexes · Updated Jan 9, 2026 · NCT05106296

Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

RecruitingPhase 1
Ages 18 and older · All sexes · Updated Dec 18, 2025 · NCT04541082

68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.

RecruitingPhase 4
Ages 18 to 100 · All sexes · Updated Nov 21, 2025 · NCT04081701

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.